Multiple Myeloma
Conditions
Interventions
single arm:CD19, BCMA CAR-T Cells Immunotherapy
Sponsors
The Third Affiliated Hospital of Kunming Medical University
Eligibility
Sex/Gender
All
Age
2 Years to 70 Years
Inclusion criteria
Inclusion criteria: 1. Aged >= 2 and = 2.0 x 10^9/LLymphocyte count > 0.5x10^9/L, Hb >= 80 g/L, PLT >= 30 x 10^9/L); 4. Non-severe allergic constitution; 5. No other serious diseases (such as autoimmune diseases, immune deficiency, organ transplantation) that conflict with this program; 6. No history of other malignant tumors; 7. Women of childbearing age must have a negative blood pregnancy test within 7 days and must use appropriate contraception during the study and for 3 months after the study.
Exclusion criteria
Exclusion criteria: 1. Pregnant or nursing women (women of childbearing age need to have a pregnancy test); 2. Severe infectious or viral diseases (HIV positive, syphilis, etc.); 3. Active viral hepatitis b or c; 4. Patients who had used amounts of glucocorticoids within 1 week; 5. Patients with severe heart, liver, renal insufficiency, diabetes and other diseases; 6. Those who have participated in other clinical studies in the past 3 months or have previously received other gene product treatments.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| CAR gene; | — |
Countries
China
Contacts
Public ContactXun Lai
The Third Affiliated Hospital of Kunming Medical University
Outcome results
None listed